SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-053972
Filing Date
2023-10-18
Accepted
2023-10-18 16:15:25
Documents
50
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q abio-20230930.htm   iXBRL 10-Q 1503966
2 EX-31.1 abio-ex31_1.htm EX-31.1 12668
3 EX-31.2 abio-ex31_2.htm EX-31.2 12527
4 EX-32.1 abio-ex32_1.htm EX-32.1 16645
  Complete submission text file 0000950170-23-053972.txt   4570612

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT abio-20230930_def.xml EX-101.DEF 77627
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abio-20230930.xsd EX-101.SCH 26801
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT abio-20230930_cal.xml EX-101.CAL 28058
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abio-20230930_pre.xml EX-101.PRE 188349
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abio-20230930_lab.xml EX-101.LAB 269378
44 EXTRACTED XBRL INSTANCE DOCUMENT abio-20230930_htm.xml XML 602289
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22873 | Film No.: 231332415
SIC: 2835 In Vitro & In Vivo Diagnostic Substances